發(fā)布時(shí)間：2018-08-30 11:10

【摘要】：目的：通過(guò)對(duì)前列腺癌(Prostate Cancer, PCa)患者多項(xiàng)免疫指標(biāo)的檢測(cè),初步評(píng)估前列腺癌患者的免疫功能狀態(tài),探討前列腺癌患者免疫功能狀態(tài)與前列腺癌臨床分期、病理分級(jí)、內(nèi)分泌治療等臨床因素的關(guān)系。 方法：分別選取前列腺癌患者28例,前列腺增生(Benign Prostatic Hyperplasia, BPH)患者16例,健康對(duì)照者10例,采集其新鮮外周血,使用流式細(xì)胞術(shù)檢測(cè)外周血CD4+、CD8+和NK細(xì)胞的百分率以及CD4+/CD8+的比值。另選取前列腺癌患者30例,前列腺增生患者17例,健康對(duì)照者(healthy men, HM)7例,采集其新鮮外周血并提取外周血淋巴細(xì)胞(peripheral blood lymphocyte, PBL),運(yùn)用運(yùn)用實(shí)時(shí)熒光定量PCR (Real-Time PCR)檢測(cè)受試者PBL中perforin、 granzyme-B的mRNA的表達(dá)水平,并進(jìn)行統(tǒng)計(jì)學(xué)分析,觀察各組免疫指標(biāo)的差異,評(píng)價(jià)各項(xiàng)免疫指標(biāo)的變化與前列腺癌臨床分期、病理分級(jí)等臨床變量之間的關(guān)系。 結(jié)果：前列腺癌組患者CD4+淋巴細(xì)胞百分比及CD4+/CD8+的比值較前列腺增生組及健康對(duì)照組顯著降低且差異有統(tǒng)計(jì)學(xué)意義(P0.05)；CD8+淋巴細(xì)胞百分比較其他兩組升高,差異有統(tǒng)計(jì)學(xué)意義(P0.05)；NK細(xì)胞百分比較前列腺增生組及健康對(duì)照組差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。高分化前列腺癌CD4+淋巴細(xì)胞百分比及CD4+/CD8+的比值高于中、低分化前列腺癌,CD8+淋巴細(xì)胞百分比低于低分化前列腺癌,差異均有統(tǒng)計(jì)學(xué)意義(P0.05),二者NK細(xì)胞百分比差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。T3期前列腺癌與T4期前列腺癌相比,CD4+/CD8+淋巴細(xì)胞百分比、CD4+/CD8+的比值及NK細(xì)胞百分比差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。無(wú)轉(zhuǎn)移前列腺癌CD4+淋巴細(xì)胞百分比及CD4+/CD8+的比值較有轉(zhuǎn)移前列腺癌明顯升高,差異有統(tǒng)計(jì)學(xué)意義(P0.05),CD8+淋巴細(xì)胞百分比低于有轉(zhuǎn)移前列腺癌且差異有統(tǒng)計(jì)學(xué)意義(P0.05),兩者NK細(xì)胞百分比差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。未行內(nèi)分泌治療前列腺癌與內(nèi)分泌治療時(shí)程4周前列腺癌相比,CD4+/CD8+、NK細(xì)胞百分比及CD4+/CD8+比值間的差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。 前列腺癌組患者perforin、granzyme-B mRNA相對(duì)表達(dá)量均顯著低于前列腺增生組及健康對(duì)照組,且差異有統(tǒng)計(jì)學(xué)意義(P0.05)。高分化前列腺癌perforin、granzyme-B mRNA相對(duì)表達(dá)量均高于中、低分化前列腺癌,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。T3期前列腺癌perforin、granzyme-B mRNA相對(duì)表達(dá)量均高于T4期前列腺癌,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。無(wú)轉(zhuǎn)移前列腺癌與有轉(zhuǎn)移前列腺癌相比,perforin、granzyme-B mRNA相對(duì)表達(dá)水平差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。未行內(nèi)分泌治療前列腺癌與內(nèi)分泌治療時(shí)程4周前列腺癌相比,perforin、granzyme-B mRNA相對(duì)表達(dá)水平差異無(wú)統(tǒng)計(jì)學(xué)意義。 結(jié)論：1.前列癌患者較前列腺增生患者和健康者機(jī)體免疫力降低。2.前列腺癌患者免疫抑制程度可能與腫瘤惡性程度和臨床進(jìn)展程度相關(guān),惡性程度越高、臨床分期越晚提示前列腺癌患者免疫抑制程度越重。3.內(nèi)分泌治療對(duì)前列腺癌患者的免疫功能無(wú)顯著影響。
[Abstract]:Objective: to evaluate the immune function of prostate cancer patients with (Prostate Cancer, PCa), and to explore the clinical stage and pathological grade of prostate cancer. The relationship between endocrine therapy and other clinical factors. Methods: 28 cases of prostate cancer, 16 cases of benign prostatic hyperplasia (Benign Prostatic Hyperplasia, BPH) and 10 cases of healthy control were collected from fresh peripheral blood. The percentage of CD4 CD8 and NK cells and the ratio of CD4 / CD8 in peripheral blood were detected by flow cytometry. In addition, 30 patients with prostate cancer, 17 patients with benign prostatic hyperplasia and 7 healthy people with (healthy men, HM) were selected. The expression of perforin, granzyme-B mRNA in PBL was detected by real-time fluorescence quantitative PCR (Real-Time PCR), and the expression of perforin, granzyme-B mRNA was analyzed statistically. To evaluate the relationship between the changes of immune indexes and clinical variables such as clinical stage and pathological grade of prostate cancer. Results: the percentage of CD4 lymphocyte and the ratio of CD4 / CD8 in prostate cancer group were significantly lower than those in benign prostatic hyperplasia group and healthy control group (P0.05). The difference was statistically significant (P0.05) the percentage of NK cells was not significantly higher than that of benign prostatic hyperplasia group and healthy control group (P0.05). The percentage of CD4 lymphocytes and the ratio of CD4 / CD8 in well-differentiated prostate cancer were higher than those in low-differentiated prostate cancer, and the percentage of CD8 lymphocytes in poorly differentiated prostate cancer was lower than that in poorly differentiated prostate cancer. There was no significant difference in the percentage of NK cells between the two groups (P0.05). There was no significant difference in the percentage of CD4 / CD8 lymphocytes and the percentage of NK cells between stage T3 prostate cancer and T4 stage prostate cancer (P0.05). The percentage of CD4 lymphocytes and the ratio of CD4 / CD8 in non-metastatic prostate cancer were significantly higher than those in metastatic prostate cancer. The percentage of CD8 lymphocytes was significantly lower than that of metastatic prostate cancer (P0.05), but there was no significant difference in the percentage of NK cells between the two groups (P0.05). There was no significant difference in the percentage of CD4 / CD8 NK cells and the ratio of CD4 / CD8 between prostate cancer without endocrine therapy and prostate cancer after 4 weeks of endocrine therapy (P0.05). The relative expression of perforin,granzyme-B mRNA in prostate cancer group was significantly lower than that in benign prostatic hyperplasia group and healthy control group (P0.05). The relative expression of perforin,granzyme-B mRNA in well-differentiated prostate cancer was higher than that in low-differentiated prostate cancer, the difference was statistically significant (P0.05). The relative expression of perforin,granzyme-B mRNA in stage T3 prostate cancer was higher than that in stage T4 prostate cancer, and the difference was statistically significant (P0.05). There was no significant difference in the relative expression of perforin granzyme-B mRNA between non-metastatic prostate cancer and metastatic prostate cancer (P0.05). There was no significant difference in the relative expression of granzyme-B mRNA between prostatic cancer without endocrine therapy and prostate cancer treated with endocrine therapy for 4 weeks. Conclusion 1. The immunity of prostatic cancer patients was lower than that of benign prostatic hyperplasia patients and healthy people. The degree of immunosuppression in patients with prostate cancer may be related to the degree of malignancy and clinical progression. The higher the degree of malignancy, the later the clinical stage indicates that the degree of immunosuppression in patients with prostate cancer is more serious. 3. Endocrine therapy had no significant effect on immune function of prostate cancer patients.
【學(xué)位授予單位】：中南大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R737.25

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 魏姍姍;佘妙容;彭琪;夏平方;;自然殺傷細(xì)胞在白血病免疫逃逸中的研究進(jìn)展[J];廣東醫(yī)學(xué);2013年22期

2 馬德民;張宗利;;肝細(xì)胞癌免疫治療的現(xiàn)狀和進(jìn)展[J];肝膽外科雜志;2014年04期

3 林城;陳雄;劉靜南;黃于芳;歐陽(yáng)學(xué)農(nóng);;PD-1/PD-L1信號(hào)通路在非小細(xì)胞肺癌免疫逃逸及其治療中的研究進(jìn)展[J];中國(guó)肺癌雜志;2014年10期

4 封全靈;王紅麗;張毅;史惠蓉;張斌;;宮頸癌患者外周血中髓源抑制細(xì)胞比例變化及CD73的表達(dá)[J];鄭州大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2014年04期

5 林澤偉;駱必偉;袁曉東;田佩凱;謝勇;歐希;劉曉平;劉吉奎;;原發(fā)性肝癌患者腫瘤浸潤(rùn)T淋巴細(xì)胞亞群分析[J];中國(guó)現(xiàn)代普通外科進(jìn)展;2013年07期

6 張磊昌;陳利生;張森;龍軍先;黃永紅;鐘武;高楓;曹云飛;;CD4~+IL-9~+細(xì)胞在大腸癌免疫微環(huán)境中的分布及臨床意義[J];中華腫瘤防治雜志;2014年06期

7 王錦國(guó);吳向未;陳雪玲;李維嘉;牛建華;;胃癌小鼠模型中T淋巴細(xì)胞檢測(cè)及初步分析[J];石河子大學(xué)學(xué)報(bào)(自然科學(xué)版);2014年03期

8 李杰;郭秋均;林洪生;;中醫(yī)藥對(duì)腫瘤免疫抑制微環(huán)境的調(diào)控作用及分子機(jī)制研究[J];世界中醫(yī)藥;2014年07期

9 吳林峰;雷小英;顏真;孫建斌;向安;;腫瘤細(xì)胞對(duì)血清補(bǔ)體殺傷耐受的機(jī)制研究[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2014年30期

10 汪繼兵;王人衛(wèi);李擎;范麗玲;;自控鍛煉對(duì)癌癥生存者細(xì)胞免疫的影響[J];武漢體育學(xué)院學(xué)報(bào);2013年08期

相關(guān)博士學(xué)位論文 前6條

1 王少鑫;CUEDC2在結(jié)腸炎相關(guān)腫瘤中作用機(jī)制的研究[D];中國(guó)人民解放軍軍事醫(yī)學(xué)科學(xué)院;2013年

2 李文斌;IL-17A/G-CSF axis對(duì)于免疫細(xì)胞的調(diào)控及其在結(jié)腸炎相關(guān)結(jié)直腸癌發(fā)生發(fā)展中的作用研究[D];北京協(xié)和醫(yī)學(xué)院;2013年

3 茆勇;負(fù)性共刺激分子B7-H1、B7-H3、B7-H4在結(jié)直腸癌演變過(guò)程中的表達(dá)規(guī)律及臨床意義[D];蘇州大學(xué);2013年

4 許鳳燕;CD27及CD70基因多態(tài)性與黑龍江省漢族婦女散發(fā)性乳腺癌的相關(guān)性研究[D];哈爾濱醫(yī)科大學(xué);2012年

5 張磊昌;CD4+IL9+T細(xì)胞在結(jié)直腸癌免疫微環(huán)境中分布、表型、分化與募集的實(shí)驗(yàn)研究[D];廣西醫(yī)科大學(xué);2014年

6 張晶;核因子-κB及干擾素調(diào)節(jié)因子3在抗腫瘤免疫中的作用[D];天津醫(yī)科大學(xué);2014年

相關(guān)碩士學(xué)位論文 前10條

1 吳丹;人源性乳腺微環(huán)境小鼠模型的移植物功能研究[D];南京醫(yī)科大學(xué);2013年

2 張志興;鼻咽非角化鱗狀細(xì)胞癌組織內(nèi)浸潤(rùn)的T淋巴細(xì)胞的表達(dá)及意義[D];廣西醫(yī)科大學(xué);2013年

3 范元春;同種異體NK細(xì)胞與人上皮性卵巢癌細(xì)胞之間的免疫編輯[D];河北醫(yī)科大學(xué);2013年

4 周鑫;烯醇化酶ENO1影響非小細(xì)胞肺癌細(xì)胞EMT的研究[D];北京協(xié)和醫(yī)學(xué)院;2013年

5 張玨;腫瘤環(huán)境影響抗感染CD8~+T細(xì)胞應(yīng)答啟動(dòng)的初步研究[D];第三軍醫(yī)大學(xué);2013年

6 陳譽(yù);MICA表達(dá)與晚期非小細(xì)胞肺癌預(yù)后關(guān)系及與CIK治療療效的初步研究[D];福建醫(yī)科大學(xué);2013年

7 楊培培;腫瘤相關(guān)巨噬細(xì)胞和調(diào)節(jié)性T細(xì)胞在胃間質(zhì)瘤中的浸潤(rùn)及意義[D];安徽醫(yī)科大學(xué);2013年

8 費(fèi)儒杉;改良二期直腸經(jīng)會(huì)陰切除手術(shù)在嵌頓性直腸脫垂中的應(yīng)用[D];浙江大學(xué);2013年

9 吳鑫;Piwil2重編程兒童成纖維細(xì)胞形成腫瘤干細(xì)胞的初步研究[D];重慶醫(yī)科大學(xué);2013年

10 史瑩玲;右美托咪定對(duì)手術(shù)患者T淋巴細(xì)胞亞群數(shù)量的影響[D];大連醫(yī)科大學(xué);2013年

，

本文編號(hào)：2212887